RE:RE:RE:That's the 2nd time TST has used "actionable" in PR re FDAThe FDA decision is not set in stone. We are far away from that. Or they will find a compromise feasable for both parts.
Or TST could appeal the agency's decision after the meeting.
The instrument herefore is called "supervisory review" if I am correct.
Epigenomics (OTCQX:EPGNY)did that successfully.
They have got the FDA approval yesterday after appealing a FDA request for more data in November 2015